PAVmed (NASDAQ:PAVM) Stock Rating Upgraded by Zacks Investment Research

PAVmed (NASDAQ:PAVMGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City. “

PAVM has been the subject of several other reports. Maxim Group reduced their target price on PAVmed to $3.00 and set a “na” rating for the company in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of PAVmed in a report on Saturday, February 12th.

Shares of NASDAQ:PAVM opened at $1.09 on Friday. PAVmed has a 12-month low of $0.94 and a 12-month high of $9.70. The business’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $2.15. The company has a market capitalization of $95.88 million, a PE ratio of -1.58 and a beta of 0.22.

PAVmed (NASDAQ:PAVMGet Rating) last issued its quarterly earnings results on Tuesday, March 29th. The company reported ($0.15) EPS for the quarter. The business had revenue of $0.30 million during the quarter. Sell-side analysts forecast that PAVmed will post -0.89 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Lido Advisors LLC lifted its stake in PAVmed by 400.0% during the first quarter. Lido Advisors LLC now owns 50,000 shares of the company’s stock worth $66,000 after purchasing an additional 40,000 shares during the last quarter. State Street Corp raised its stake in shares of PAVmed by 8.8% during the first quarter. State Street Corp now owns 1,496,536 shares of the company’s stock worth $1,975,000 after purchasing an additional 120,691 shares during the last quarter. Verition Fund Management LLC acquired a new position in PAVmed during the first quarter worth $196,000. Charles Schwab Investment Management Inc. grew its holdings in PAVmed by 5.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 195,167 shares of the company’s stock worth $258,000 after acquiring an additional 10,458 shares during the period. Finally, Vanguard Group Inc. grew its holdings in PAVmed by 2.9% during the first quarter. Vanguard Group Inc. now owns 4,216,982 shares of the company’s stock worth $5,567,000 after acquiring an additional 116,997 shares during the period. 30.31% of the stock is owned by institutional investors and hedge funds.

About PAVmed (Get Rating)

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.

Featured Stories

Get a free copy of the Zacks research report on PAVmed (PAVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.